Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.

Clinical cancer research : an official journal of the American Association for Cancer Research - 15 Oct 2013

Warren Robert S, Atreya Chloe E, Niedzwiecki Donna, Weinberg Vivian K, Donner David B, Mayer Robert J, Goldberg Richard M, Compton Carolyn C, Zuraek Marlene B, Ye Cynthia, Saltz Leonard B, Bertagnolli Monica M

Abstract excerpt

PURPOSE: The TP53 tumor suppressor is frequently mutated in colon cancer, but the influence of such mutations on survival remains controversial. We investigated whether mutations in the DNA-binding domain of TP53 are associated with survival in stage III colon cancer. EXPERIMENTAL DESIGN: The imp...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Chemotherapy, Adjuvant

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Colonic Neoplasms

Share to Microsatellite Instability

Share to Molecular Conformation

Share to Neoplasm Staging

Share to Sex Factors

Source

Open in PubMed Open full text

Identifiers

PMID: 23983256
DOI: 10.1158/1078-0432.CCR-13-0351
PMCID: PMC4122229

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-23983256-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803.PMID 23983256Read ↗

TP53 Mutational Status and Prediction of Benefit from Adjuvant 5-Fluorouracil in Stage III Colon Cancer Patients.Semantic proximity Read ↗

The TP53 colorectal cancer international collaborative study on the prognostic and predictive significance of p53 mutation: influence of tumor site, type of mutation, and adjuvant treatment.Semantic proximity Read ↗

Gender-specific genomic profiling in metastatic colorectal cancer patients treated with 5-fluorouracil and oxaliplatin.Semantic proximity Read ↗

TP53 and long-term prognosis in colorectal cancer: mutations in the L3 zinc-binding domain predict poor survival.Semantic proximity Read ↗

Is it Possible to Predict Benefit from 5FU Adjuvant Therapy in Stage III Colon Cancer Patients?Semantic proximity Read ↗

Mutated p53 gene is an independent adverse predictor of survival in colon carcinoma.Semantic proximity Read ↗

Sex-Related Differences in Impact on Safety of Pharmacogenetic Profile for Colon Cancer Patients Treated with FOLFOX-4 or XELOX Adjuvant Chemotherapy.Semantic proximity Read ↗

Gender-Related Survival Differences Associated with<i>EGFR</i>Polymorphisms in Metastatic Colon CancerSemantic proximity Read ↗

Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation.Semantic proximity Read ↗

Association of p53 mutations with short survival in colorectal cancer.Semantic proximity Read ↗

TP53 mutations in advanced colorectal cancer: the dark side of the moon.Semantic proximity Read ↗

Association of methylenetetrahydrofolate reductase gene polymorphisms and sex-specific survival in patients with metastatic colon cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.